Compare TPCS & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPCS | CTSO |
|---|---|---|
| Founded | 1956 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 38.2M |
| IPO Year | 2008 | 2008 |
| Metric | TPCS | CTSO |
|---|---|---|
| Price | $3.67 | $0.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 56.0K | ★ 108.2K |
| Earning Date | 02-17-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 64.20 | ★ 65.79 |
| EPS | N/A | N/A |
| Revenue | ★ $34,031,000.00 | $22,503,908.00 |
| Revenue This Year | N/A | $12.21 |
| Revenue Next Year | N/A | $20.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.72 | ★ 48.53 |
| 52 Week Low | $2.29 | $0.50 |
| 52 Week High | $6.25 | $1.39 |
| Indicator | TPCS | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 59.06 | 39.78 |
| Support Level | $3.40 | $0.50 |
| Resistance Level | $3.91 | $0.74 |
| Average True Range (ATR) | 0.20 | 0.06 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 81.48 | 41.26 |
Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.